TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27105332

Group type: EXPERIMENTAL
Intervention: Individual‐Family Psychoeducational Psychotherapy (PEP)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: omega‐3 supplementation
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Combination of omega‐3 and PEP
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 29625834

Group type: EXPERIMENTAL
Intervention: Guided Internet-based cognitive behavioral treatment (ICBT) for 12 weeks
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Unguided Internet-based cognitive behavioral treatment (ICBT) for 12 weeks
Number of subjects: 111

Group type: COMPARATOR
Intervention: Waitlist control (WL)
Number of subjects: 111
Study: 26597925

Group type: EXPERIMENTAL
Intervention: Simvastatin plus ezetimibe
Number of subjects: 9270
Study: 24609919

Group type: EXPERIMENTAL
Intervention: 12 month intervention group (three face to face visits with a lifestyle counsellor plus monthly 15 minute telephone calls)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Control group (weight loss booklet only)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: 12 month intervention group
Number of subjects: 329
Study: 23168106

Group type: EXPERIMENTAL
Intervention: Magnification lenses
Number of subjects: 14

Group type: COMPARATOR
Intervention: Traditional safety lenses
Number of subjects: 14
Study: 19369056

Group type: EXPERIMENTAL
Intervention: EGG group (640 mg additional cholesterol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CR (10-15% en)
Number of subjects: 0
Study: 17671956

Group type: EXPERIMENTAL
Intervention: Carbofilm coated stent (Carbosten)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 0
Study: 15574664

Group type: EXPERIMENTAL
Intervention: Implementation intentions
Number of subjects: 0

Group type: COMPARATOR
Intervention: No implementation intentions
Number of subjects: 0
Study: 11880821

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.3 g x kg(‐1) x d(‐1) for 7 days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 10511768

Group type: EXPERIMENTAL
Intervention: Captopril (0.7 mg/kg)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Captopril (0.7 mg/kg) and Furosemide (1 mg/kg)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Furosemide (1 mg/kg)
Number of subjects: 82
Study: 8835246

Group type: EXPERIMENTAL
Intervention: sulphasalazine (Salazopyrin)
Number of subjects: 23
Study: 2046374

Group type: EXPERIMENTAL
Intervention: Special follow-up group (EAP clients with routine contacts from a follow-up counselor)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Regular care group (EAP clients receiving follow-up only as needed)
Number of subjects: 325
Study: 6791883

Group type: EXPERIMENTAL
Intervention: Nadolol (17 patients)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (20 patients)
Number of subjects: 37
Study: 31548244

Group type: EXPERIMENTAL
Intervention: 3Mdiet
Number of subjects: 28

Group type: COMPARATOR
Intervention: 6Mdiet
Number of subjects: 28
Study: 29103749

Group type: EXPERIMENTAL
Intervention: Cisplatin plus taxanes (TP)
Number of subjects: 806

Group type: COMPARATOR
Intervention: Cisplatin plus fluorouracil (PF)
Number of subjects: 806
Study: 26932302

Group type: EXPERIMENTAL
Intervention: Empagliflozin 12.5 mg/metformin 1,000 mg FDC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual tablets of empagliflozin and metformin
Number of subjects: 0
Study: 24956099

Group type: EXPERIMENTAL
Intervention: Collagen matrix (CM) plus coronally advanced flap (CAF)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Coronally advanced flap (CAF)
Number of subjects: 32
Study: 22228104

Group type: EXPERIMENTAL
Intervention: G17DT
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: G17DT (responders)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo (nonresponders)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo (overall)
Number of subjects: 154
Study: 18434221

Group type: EXPERIMENTAL
Intervention: Active physical treatment (APT) - 10 weeks of aerobic training and muscle strengthening of back extensors
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Graded activity plus problem solving training (GAP) - 10 weeks of gradual assumption of patient relevant activities based on operant‐behavioral principles and problem solving training
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Combination treatment (CT) - APT combined with GAP
Number of subjects: 172

Group type: COMPARATOR
Intervention: APT
Number of subjects: 172

Group type: COMPARATOR
Intervention: GAP
Number of subjects: 172
Study: 17126963

Group type: EXPERIMENTAL
Intervention: Modified vaccinia Ankara (MVA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16306196

Group type: EXPERIMENTAL
Intervention: Combined treatment with indomethacin (0.1 mg/kg/24 h for three doses) and L‐NMMA (infusion for 72 hours)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Indomethacin (0.1 mg/kg/24 h for three doses)
Number of subjects: 50
Study: 12693434

Group type: EXPERIMENTAL
Intervention: Cognitive Adaptation Training (CAT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control condition (therapist time and environmental changes unrelated to cognitive deficits)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Follow-up only
Number of subjects: 45
Study: 10099034

Group type: EXPERIMENTAL
Intervention: Nicardipine (60 or 90 mg/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nicardipine and Placebo
Number of subjects: 20
Study: 8574862

Group type: EXPERIMENTAL
Intervention: Fermented maize-soybean porridge (F)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-fermented maize-soybean porridge (NF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditionally fermented maize-only porridge (P)
Number of subjects: 0
Study: 1479277

Group type: EXPERIMENTAL
Intervention: Abscess tonsillectomy
Number of subjects: 53

Group type: COMPARATOR
Intervention: Incision and drainage
Number of subjects: 53
Study: 6232263

Group type: EXPERIMENTAL
Intervention: Nomifensine maleate (100-200 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31421635

Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) treatment (250 mg for 2 days, 500 mg for 2 days, 750 mg for 3 days, and 1000 mg for 5 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 29247343

Group type: EXPERIMENTAL
Intervention: Caffeine-maltodextrin mouth rinse (MR: 0.3 g/25 ml CAF: 1.6g/25 ml MALT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Caffeine-maltodextrin mouth rinse (MR)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PLAC: 25 ml artificial saliva)
Number of subjects: 10
Study: 27965251

Group type: EXPERIMENTAL
Intervention: AKUD trial (app‐administered self‐care acupressure)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Financial compensation of €30
Number of subjects: 25
Study: 25701338

Group type: EXPERIMENTAL
Intervention: ω-3 supplementation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 23886416

Group type: EXPERIMENTAL
Intervention: 4.3 Gy × 10 fractions (target dose 43 Gy)
Number of subjects: 1566

Group type: COMPARATOR
Intervention: 2.5 Gy × 20 fractions (target dose 50 Gy)
Number of subjects: 1566

Group type: EXPERIMENTAL
Intervention: Photon beams for parasternal fields
Number of subjects: 1566

Group type: EXPERIMENTAL
Intervention: 4.3 Gy regimen
Number of subjects: 1566
Study: 20617051

Group type: EXPERIMENTAL
Intervention: PA intervention (one hour of moderate exercise three times a week for three months)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control (normal exercise schedule provided by the school)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: PA intervention
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control
Number of subjects: 160
Study: 17694310

Group type: EXPERIMENTAL
Intervention: Gefitinib 1000 mg/day with temozolomide for patients on EIAEDs
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg/day with temozolomide for patients not on EIAEDs
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Gefitinib 500 mg/day
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Gefitinib and temozolomide combination
Number of subjects: 26
Study: 17019957

Group type: EXPERIMENTAL
Intervention: Low‐intensive laser radiation (LILR) monotherapy
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Low‐intensive laser radiation (LILR) plus conventional drug therapy (CDT)
Number of subjects: 466

Group type: COMPARATOR
Intervention: Conventional drug therapy (CDT) only
Number of subjects: 466
Study: 14620099

Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 10780761

Group type: EXPERIMENTAL
Intervention: zafirlukast 80 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: zafirlukast 20 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study: 9219407

Group type: EXPERIMENTAL
Intervention: Pictorial flashcard one‐to‐one education
Number of subjects: 201
Study: 8205314

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 143
Study: 3305136

Group type: EXPERIMENTAL
Intervention: Manometric assessment
Number of subjects: 68

Group type: COMPARATOR
Intervention: Visual assessment (Control)
Number of subjects: 68
Study: 29663430

Group type: EXPERIMENTAL
Intervention: B. Braun
Number of subjects: 12

Group type: COMPARATOR
Intervention: FMC
Number of subjects: 12
Study: 26918558

Group type: EXPERIMENTAL
Intervention: Low-intensity WBV
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: High-intensity WBV
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control (no WBV)
Number of subjects: 84
Study: 25291130

Group type: EXPERIMENTAL
Intervention: Active formulation containing 250 mg of tara gum and 1 billion viable cells of S. thermophilus ST10
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo formulation
Number of subjects: 25
Study: 22837118

Group type: EXPERIMENTAL
Intervention: Meperedine (0.4 mg/Kg/IV)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg/IV)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal Saline (Control)
Number of subjects: 90
Study: 20600556

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine (Consepsis)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 80
Study: 18038601

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine in complex therapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Mucaltin (control group)
Number of subjects: 35
Study: 16129716

Group type: EXPERIMENTAL
Intervention: High-calcium diet (1400 mg of calcium)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Moderate-calcium diet (800 mg of calcium)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High-calcium, increased fiber, low glycemic index diet
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control diet (standard diet with 800 mg of calcium)
Number of subjects: 90
Study: 11872102

Group type: EXPERIMENTAL
Intervention: 2 mL/hour
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 20 mL/hour
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 50 mL/hour
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 100 mL/hour
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: All administration sets
Number of subjects: 4
Study: 7852725

Group type: EXPERIMENTAL
Intervention: Liquid soap
Number of subjects: 10

Group type: COMPARATOR
Intervention: Chlorhexidine gluconate
Number of subjects: 10
Study: 3416310

Group type: EXPERIMENTAL
Intervention: 10-ethyl-10-deazaaminopterin (10-EDAM) i.v. at dosage levels ranging from 5 to 120 mg/m2
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 10-EDAM i.v. weekly x 3 schedule (35 patients) or weekly schedule (27 patients)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 10-EDAM i.v. weekly at 80 mg/m2 or 100 mg/m2 weekly for 3 weeks
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Pharmacokinetic studies at 5, 30, and 100 mg/m2 dosage levels
Number of subjects: 62
Study: 31494486

Group type: EXPERIMENTAL
Intervention: Contingent valuation survey measuring willingness to pay for a 2% mortality risk reduction.
Number of subjects: 4000
Study: 28404133

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a plus nucleos(t)ide analogues
Number of subjects: 185

Group type: COMPARATOR
Intervention: Nucleos(t)ide analogues alone
Number of subjects: 185
Study: 25523060

Group type: EXPERIMENTAL
Intervention: Individual dietetic consultations (8 sessions)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Individual dietetic consultations (8 sessions, attended all)
Number of subjects: 30
Study: 24640432

Group type: EXPERIMENTAL
Intervention: 0.454% stabilized stannous fluoride (SnF2) dentifrice
Number of subjects: 96

Group type: COMPARATOR
Intervention: Triclosan/copolymer dentifrice
Number of subjects: 96
Study: 21631949

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: RT-qPCR analysis
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Transcriptome analysis
Number of subjects: 327
Study: 19816648

Group type: EXPERIMENTAL
Intervention: Monthly ibandronate 150 mg for 3 months
Number of subjects: 365

Group type: COMPARATOR
Intervention: Weekly risedronate 35 mg for 12 weeks
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Monthly ibandronate
Number of subjects: 365

Group type: COMPARATOR
Intervention: Weekly risedronate
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 365
Study: 16420193

Group type: EXPERIMENTAL
Intervention: Physical examination protocol for identifying biomechanical and soft-tissue abnormalities
Number of subjects: 111
Study: 15344186

Group type: COMPARATOR
Intervention: Experimental treatment
Number of subjects: 0
Study: 11575038

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (osteopathic structural examination only)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both groups received conventional therapy (antidepressant paroxetine plus weekly psychotherapy for 8 weeks)
Number of subjects: 17
Study: 9148651

Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Open phase (previous nonresponders receiving erythropoietin)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hematologic response
Number of subjects: 40
Study: 8120155

Group type: EXPERIMENTAL
Intervention: Brofaromine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 3054783

Group type: EXPERIMENTAL
Intervention: Calf lung surfactant extract in saline
Number of subjects: 34

Group type: COMPARATOR
Intervention: Saline alone
Number of subjects: 34
Study: 5309529

Group type: EXPERIMENTAL
Intervention: Intradermal jet injection using diluted smallpox vaccine with a titre of 10(6.3) TCID(50)/ml
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Intradermal jet injection using diluted smallpox vaccine with a titre of 10(7.0) TCID(50)/ml
Number of subjects: 625

Group type: COMPARATOR
Intervention: Multiple-pressure vaccination using undiluted vaccine
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Intradermal jet injection using diluted smallpox vaccine with a titre of 10(6.0) TCID(50)/ml
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Intradermal jet injection using diluted smallpox vaccine with a titre of 10(5.0) TCID(50)/ml
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Jet vaccination
Number of subjects: 625
Study: 31292007

Group type: EXPERIMENTAL
Intervention: Intracavitary steroids (80 mg of methylprednisolone)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 212
Study: 28287057

Group type: EXPERIMENTAL
Intervention: Story Method (mnemonic strategy with visualization and narrative structure)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Imagery (mnemonic strategy of simple visualization of words)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control condition (non-trained, equivalent exposure to training word lists)
Number of subjects: 61
Study: 25269831

Group type: EXPERIMENTAL
Intervention: Peginterferon‐α‐2b
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 72
Study: 22584648

Group type: EXPERIMENTAL
Intervention: Surgical ventricular reconstruction (SVR)
Number of subjects: 1000
Study: 21811797

Group type: EXPERIMENTAL
Intervention: tramadol/APAP (37.5 mg/325 mg)
Number of subjects: 143

Group type: COMPARATOR
Intervention: NSAID
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: tramadol/APAP
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: tramadol/APAP and NSAID combination therapy
Number of subjects: 143
Study: 19933961

Group type: EXPERIMENTAL
Intervention: Case management (CM) program led by nurses and dietitians
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Case management (CM) program
Number of subjects: 419

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 419
Study: 17314577

Group type: EXPERIMENTAL
Intervention: 30 mg M6G
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 15543797

Group type: EXPERIMENTAL
Intervention: Computerized nipple detection method
Number of subjects: 744
Study: 11453311

Group type: EXPERIMENTAL
Intervention: 200 mg moxifloxacin once daily for 10 days
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: 400 mg moxifloxacin once daily for 10 days
Number of subjects: 229

Group type: COMPARATOR
Intervention: Clarithromycin 500 mg twice daily for 10 days
Number of subjects: 229
Study: 9656942

Group type: EXPERIMENTAL
Intervention: Pittsburgh rule
Number of subjects: 934

Group type: COMPARATOR
Intervention: Ottawa rule
Number of subjects: 934
Study: 8092599

Group type: COMPARATOR
Intervention: 0 mL/kg magnesium citrate
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 4 mL/kg magnesium citrate
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 6 mL/kg magnesium citrate
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 8 mL/kg magnesium citrate
Number of subjects: 64
Study: 3337929

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg/day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Naproxen 1000 mg/day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Naproxen 1500 mg/day
Number of subjects: 18
Study: 29150968

Group type: EXPERIMENTAL
Intervention: 453 nm blue light irradiation for 30 minutes after skin perturbation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no light administered)
Number of subjects: 22
Study: 28277990

Group type: EXPERIMENTAL
Intervention: Hyperoxygenated fatty acids (HOFA)
Number of subjects: 152
Study: 26032041

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 24127200

Group type: EXPERIMENTAL
Intervention: Naproxen submicron particle capsules 200 mg
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Naproxen tablets 250 mg
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Naproxen submicron particle capsules 400 mg
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Naproxen tablets 500 mg
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study: 20805762

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated pins
Number of subjects: 40

Group type: COMPARATOR
Intervention: Titanium-alloy pins
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 18080339

Group type: EXPERIMENTAL
Intervention: Telbivudine 600 mg daily
Number of subjects: 332

Group type: COMPARATOR
Intervention: Lamivudine 100 mg daily
Number of subjects: 332
Study: 16538941

Group type: EXPERIMENTAL
Intervention: Mitigator Sting and Bite Treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Calamine lotion
Number of subjects: 24
Study: 12683506

Group type: EXPERIMENTAL
Intervention: Alcohol-based hand rub
Number of subjects: 0

Group type: COMPARATOR
Intervention: Soap and water (control)
Number of subjects: 0
Study: 11113407

Group type: EXPERIMENTAL
Intervention: Higher dose of propafenone (450 to 675 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard dose of propafenone with low-dose quinidine (150 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Standard dose of propafenone plus quinidine (600 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Overall treatment (combination of all treatments)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Uncontrolled AF
Number of subjects: 60
Study: 9082591

Group type: EXPERIMENTAL
Intervention: Intravascular laser therapy
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 129
Study: 1487096

Group type: EXPERIMENTAL
Intervention: Counseling‐based aural rehabilitation program with hearing aids
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Hearing aids only
Number of subjects: 31

Group type: COMPARATOR
Intervention: Neither hearing aids nor counseling‐based AR
Number of subjects: 31